DYNAVAX TECHNOLOGIES CORP
dynavax.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q3 FY2025 10-Q, filed Nov 5, 2025. Its latest SEC filing is a 15-12G from Feb 20, 2026.
10-Q for Q3 FY2025, filed Nov 5, 2025
The sections below describe the company as of the FY2024 annual report.
What Did They Do?
Sells an adult hepatitis B vaccine to healthcare distributors and develops vaccine candidates and adjuvants with vaccine developers.
10-K for FY2024, filed Feb 20, 2025We are a commercial stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against…View ↗
Our first marketed product, HEPLISAV-B [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the United States ("U.S."), the…View ↗
We are advancing a pipeline of differentiated product candidates that leverage our CpG 1018 adjuvant to develop improved vaccines in…View ↗
Additionally, we manufacture and have supplied in the past CpG 1018 adjuvant, the adjuvant used in HEPLISAV-B, through both commercial…View ↗
All of our HEPLISAV-B sales in the U.S. are to certain wholesalers and specialty distributors whose principal customers include independent…View ↗
How Did They Make Money?
HEPLISAV-B is sold to wholesalers and specialty distributors, who generally pay shortly after delivery. For CpG 1018 reserved for Clover, payment is due at an agreed settlement or after Clover delivers its vaccine to a customer or receives payment from one.
10-K for FY2024, filed Feb 20, 2025We sell HEPLISAV-B to a limited number of wholesalers and specialty distributors in the U.S. (collectively, our “Customers”).View ↗
Revenues from product sales are recognized when we have satisfied our performance obligation, which is the transfer of control of our…View ↗
For CpG 1018 adjuvant reserved for Clover under the CEPI Agreement, Clover is obligated to pay us the purchase price upon the earliest of…View ↗
$277.2M
-
10-K for FY2024, filed Feb 21, 2025
$277.2M ↗
Who Were Their Customers?
In the U.S., wholesalers and specialty distributors buy HEPLISAV-B for resale to hospitals, clinics, public health and government facilities, and pharmacies; one distributor buys it in Germany. Vaccine developers also work with Dynavax on CpG 1018 supply and research collaborations.
10-K for FY2024, filed Feb 20, 2025All of our HEPLISAV-B sales in the U.S. are to certain wholesalers and specialty distributors whose principal customers include independent…View ↗
All of our HEPLISAV-B sales in the U.S. are to certain wholesalers and specialty distributors whose principal customers include independent…View ↗
Additionally, we manufacture and have supplied in the past CpG 1018 adjuvant, the adjuvant used in HEPLISAV-B, through both commercial…View ↗
Did Revenues Turn Into Profits?
Yes. It kept 10 cents of every revenue dollar as net income in FY2024.
10-K for FY2024, filed Feb 21, 2025
How Were They Changing?
-
Feb 10, 2026
The merger was completed
Sources
8-K, filed Feb 10, 2026
The consummation of the Merger constitutes a Share Exchange Event, a Fundamental Change and a Make-Whole Fundamental Change (each as…View ↗
-
Dec 29, 2025
Sanofi agreed to acquire Dynavax
The agreement calls for a cash offer followed by a merger if conditions are met.
Sources
8-K, filed Dec 29, 2025
On December 23, 2025, Dynavax Technologies Corporation, a Delaware corporation (the “Company” or “Dynavax”), entered into an Agreement and…View ↗
-
Nov 5, 2025
Dynavax reiterated 2025 HEPLISAV-B revenue guidance
It kept its full-year product revenue range at $315 to $325 million.
Sources
8-K, filed Nov 5, 2025
HEPLISAV-B® quarterly net product revenue of $90 million, a 13% YoY increase; reiterates full year 2025 HEPLISAV-B® net product revenue…View ↗
Grew. Revenue grew 6.0x in 4 years, from $46.6M in FY2020 to $277.2M in FY2024, about 56% a year.
Who Did They Compete With?
Competes with Pfizer, BioNTech, Curevo Vaccine, Moderna, GSK, Merck, VBI Vaccines, Sanofi, Bavarian Nordic, Emergent BioSolutions, Novavax, Medicago, Valneva, AstraZeneca, and Johnson & Johnson
10-K for FY2024, filed Feb 20, 2025The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong…View ↗
Loading...
